Research Paper Volume 13, Issue 2 pp 1742—1764
DNA methylation perturbations may link altered development and aging in the lung
- 1 Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA
- 2 Children's Mercy Hospital and Clinics, Kansas City, MO 64108, USA
- 3 Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA
Received: September 2, 2020 Accepted: December 18, 2020 Published: January 19, 2021
https://doi.org/10.18632/aging.202544How to Cite
Copyright: © 2021 Kachroo et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Fetal perturbations in DNA methylation during lung development may reveal insights into the enduring impacts on adult lung health and disease during aging that have not been explored altogether before.
We studied the association between genome-wide DNA-methylation and post-conception age in fetal-lung (n=78, 42 exposed to in-utero-smoke (IUS)) tissue and chronological age in adult-lung tissue (n=160, 114 with Chronic Obstructive Pulmonary Disease) using multi-variate linear regression models with covariate adjustment and tested for effect modification by phenotypes. Overlapping age-associations were evaluated for functional and tissue-specific enrichment using the Genotype-Tissue-Expression (GTEx) project.
We identified 244 age-associated differentially methylated positions and 878 regions overlapping between fetal and adult-lung tissues. Hyper-methylated CpGs (96%) were enriched in transcription factor activity (FDR adjusted P=2x10-33) and implicated in developmental processes including embryonic organ morphogenesis, neurogenesis and growth delay. Hypo-methylated CpGs (2%) were enriched in oxido-reductase activity and VEGFA-VEGFR2 Signaling. Twenty-one age-by-sex and eleven age-by-pack-years interactions were statistically significant (FDR<0.05) in adult-lung tissue.
DNA methylation in transcription factors during development in fetal lung recapitulates in adult-lung tissue with aging. These findings reveal molecular mechanisms and pathways that may link disrupted development in early-life and age-associated lung diseases.
Introduction
DNA methylation represents an epigenetic mark with a critical role in early life development and aging [1] that differs across tissues [2]. Previous studies in ageing research have emphasized adulthood, however increasing evidence has highlighted that age-associated cognitive decline as well as adverse later life health outcomes, for example, depend largely on epigenetic programming or adaptations during fetal development [3]. With the complex reprogramming during early-life stages, interplay of dynamic DNA methylation, chromatin marks and environmental effects during the life course make it further complicated to identify age-related versus cumulative life-course manifestations of the genome [4, 5]. Prenatal and lifetime exposures have a tremendous impact on both short- and long-term consequences mediated through epigenetic mechanisms and may contribute to a broad spectrum of immune responses, respiratory, cardiovascular and age-related diseases in later life [6, 7]. Evidence suggests impact of hypo- and hyper-methylation [8] including an altered epigenetic state on several age-associated neurological functions and human disease [9]. A recent meta-analysis identified several novel age-associated differentially methylated CpG sites in newborns and children reflective of processes critical to development [10]. Further efforts have identified the role of sex [11] and race-specific [12] differential methylation in blood along the aging process or associated pathologies. Fetal tissue DNA methylation changes associated with post-conception age and sex have been suggested to reflect brain development and are supportive of the idea that aging processes start early in life [13]. Previously, strong tissue-specific age associations with DNA methylation and gene expression have been identified in fetal and adult human livers [14], however, there is a paucity of previously reported tissue-specific studies in the literature and none for lung. Therefore, identifying more accurate biomarkers in lung tissue may merit further investigation to identify individuals at risk for age-associated lung function decline.
Recent studies have identified DNA methylation at selected CpGs to strongly predict chronological [15–21] age, constituting the epigenetic clock [21]. This may be especially useful to identify or differentiate individuals at the greatest risk for age-related health disparities and conditions. There is also a growing interest in understanding the role of epigenetic age acceleration or deceleration during the intrauterine period and adulthood. A significant association was observed between prenatal exposure to tobacco smoke and the risk of accelerated aging at birth [22], suggestive of developmental effects during childhood and the biomarker potential of age acceleration in adulthood [23]. However, limited agreement with low to moderate correlations have been observed between different epigenetic clocks estimating biological age owing to the various aspects captured by them including mortality risk, smoking, lifespan and time to death [21, 24].
To our knowledge, epigenetic links between fetal lung development and age-associated epigenetic marks in adult lung tissue (including DNA methylation age) have not been extensively explored. In this study, we performed a comparative analysis of age associated differential methylation and DNA methylation age in fetal and adult lung tissues and evaluated effect modification of age associations as a marker of development by sex and smoke exposure. Given that chronic lung diseases may be impacted by both altered lung development and accelerated aging processes, investigating age associated DNA methylation may inform new insights into lung diseases of aging, including chronic obstructive lung disease (COPD).
Results
Age-associated differential methylation in fetal and adult lung tissues
The IUS-exposed and unexposed samples did not differ by mean gestational age of the percentage of males and females in the fetal lung dataset (Table 1). 94,834 CpGs (27.1%) were significantly associated with fetal age (FDR <0.05; Supplementary Table 1,Figure 1, Supplementary Figure 1) and 35,846 (10.3%) age-associated differentially methylated positions (aDMPs) remained at a Bonferroni significance threshold (P<1.43x10-7). Of the 94,834 CpGs, 40,836 sites were relatively hypo-methylated and 53,998 sites were relatively hyper-methylated with increasing age (Supplementary Figure 2A) and were strongly enriched in gene body and 3’UTRs (Hypergeometric P-Value<2.2x10-16, P-Value=5.4x10-62 respectively) regions. Of the top 20 significant age-associated DMPs, 11 were located in CpG shores and their top associated genes included C17orf96 and CASZ1 (Table 2A). Twelve CpGs were also significantly associated with age at an absolute difference in methylation of at least 1% and with most sites increasing in methylation with age; their top associated genes included IGFBP1 and MEGF11 (Supplementary Figure 2A). In our fetal lung aDMPs, we also found previously discussed differentially methylated age-associations identified in fetal brain tissue [13] including SFRP1, NR4A2 and SHANK2.
Table 1. Overall clinical characteristics in fetal and adult lung tissue (ALT) datasets.
| Fetal lung tissue (n=78) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| All subjects (n = 78) | IUS-Exposed (n = 42) | Unexposed (n = 36) | P-value | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Post-Conception Age (days), mean (SD) | 88.7 (16) | 86 (16.4) | 91.9 (15.2) | 0.1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Chronological Age (years), mean (SD) | -0.50 (0.04) | -0.50 (0.04) | -0.49 (0.04) | 0.1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DNAmAge (years), mean (SD) | 0.50 (0.30) | 0.41 (0.28) | 0.60 (0.30) | 8.1x10-3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Age Acc. difference, mean (SD) | 0.99 (0.27) | 0.92 (0.25) | 1.08 (0.27) | 7.1x10-3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Age Acc. residual, mean (SD) | 0.00 (0.20) | -0.04 (0.17) | 0.05 (0.21) | 0.03 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sex, n (%) | 0.84 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Female | 28 (36) | 16 (38) | 12 (33) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Male | 50 (64) | 26 (62) | 24 (67) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Adult lung tissue (n=160) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| All subjects (n = 160) | With COPD (n = 114) | Without COPD (n = 46) | P-value | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Age (years), mean (SD) | 63.9 (7.4) | 63.4 (6.7) | 65.3 (8.9) | 0.19 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DNAmAge (years), mean (SD) | 66.8 (6.6) | 66.4 (6.2) | 67.7 (7.4) | 0.33 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Age Acc. difference, mean (SD) | 2.8 (5.1) | 3 (4.4) | 2.3 (6.7) | 0.50 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Age Acc. Residual, mean (SD) | 0.00 (4.5) | 0.01 (4) | -0.04 (5.5) | 0.96 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sex, n (%) | 0.31 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Female | 89 (56) | 60 (53) | 29 (63) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Male | 71 (44) | 54 (47) | 17 (37) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Race, n (%) | 0.78 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| African American | 25 (16) | 19 (17) | 6 (13) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| White | 131 (81.9) | 92 (80.7) | 39 (84.8) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Others | 4 (2.5) | 3 (2.6) | 1 (2.2) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time since quitting (months), mean (SD) | 112 (113) | 181 (139.9) | 84.7 (87.2) | 6.7x10-5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LAA-950, mean (SD) | 0.3 (0.2) | 0.3 (0.1) | 0.0 (0.1) | <2.2x10-16 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pack-years | 53.3 (27.8) | 61.2 (26.4) | 33.6 (20.5) | 1.6x10-10 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Significance of difference was evaluated using two-sample t-test for continuous variables and chi-squared test for categorical variables except race where fisher test was used due to smaller number of samples in individual categories. Missing data: Time since quitting data (months) was missing for 1 subject without COPD, fraction of lung voxels with low attenuation areas at less than -950 Hounsfield Units (LAA-950) was missing for 27 subjects without COPD and 28 COPD subjects. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abbreviations: SD, standard deviation; n, number of subjects; DNAmAge, DNA methylation or epigenetic age; Acc., Acceleration. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Figure 1. Manhattan plot depicting significance on y-axis and distribution of CpGs across all chromosomes on x-axis for fetal lung dataset (top panel) and adult lung dataset associations with age (bottom panel). Top 20 CpGs in both datasets have been highlighted in green. The two red lines represent the CpG sites significant at an FDR<0.05 and at a Bonferroni threshold (0.05/number of tests) in fetal and adult lung datasets.
Table 2A. Age-associated differential methylation in the fetal lung tissue datasets.
| CG site | UCSC Gene | CHR | MAPINFO | Island | Gene context | Coef | AveBeta | P-Value | Adjusted P | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cg14651082 | NA | 12 | 125,145,939 | S_Shore | 0.004 | 0.26 | 1.67E-37 | 5.82E-32 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cg00964751 | C17orf96 | 17 | 36,828,900 | N_Shore | 1stExon | 0.005 | 0.32 | 9.66E-37 | 1.55E-31 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cg01821043 | CASZ1 | 1 | 10,766,044 | S_Shore | 5'UTR | 0.005 | 0.60 | 2.09E-36 | 1.55E-31 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cg03955927 | LOC100132215 | 2 | 63,272,232 | Island | Body | 0.007 | 0.66 | 2.19E-36 | 1.55E-31 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cg05457903 | PLEC1 | 8 | 145,052,304 | Island | TSS1500 | 0.004 | 0.28 | 2.23E-36 | 1.55E-31 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cg03389701 | DLEU7 | 13 | 51,418,221 | S_Shore | TSS1500 | 0.004 | 0.47 | 5.03E-36 | 2.93E-31 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cg25133130 | MAP3K6 | 1 | 27,687,685 | Island | Body | 0.004 | 0.43 | 1.79E-35 | 8.93E-31 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cg09018299 | TNRC6A | 16 | 24,748,339 | OpenSea | Body | -0.006 | 0.72 | 4.01E-35 | 1.75E-30 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cg24025567 | CUX1 | 7 | 101,505,662 | OpenSea | Body | 0.003 | 0.47 | 6.38E-35 | 2.31E-30 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cg11067714 | PURA | 5 | 139,492,230 | N_Shore | TSS1500 | 0.006 | 0.34 | 6.74E-35 | 2.31E-30 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cg14205663 | NR2F2 | 15 | 96,872,827 | N_Shore | TSS1500 | 0.005 | 0.29 | 7.48E-35 | 2.31E-30 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cg25903143 | NA | 11 | 68,920,466 | OpenSea | 0.006 | 0.25 | 8.33E-35 | 2.31E-30 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cg11654900 | NA | 1 | 51,444,685 | S_Shore | 0.009 | 0.26 | 8.58E-35 | 2.31E-30 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cg13803234 | RAD51L1 | 14 | 68,830,813 | OpenSea | Body | 0.005 | 0.50 | 9.65E-35 | 2.38E-30 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cg00079023 | PURA | 5 | 139,492,535 | N_Shore | TSS1500 | 0.003 | 0.18 | 1.02E-34 | 2.38E-30 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cg10681992 | TBC1D14 | 4 | 6,964,527 | OpenSea | Body | 0.004 | 0.62 | 1.62E-34 | 3.53E-30 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cg05878390 | MAB21L2 | 4 | 151,502,935 | N_Shore | TSS200 | 0.007 | 0.23 | 2.36E-34 | 4.84E-30 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cg19791727 | NA | 10 | 21,798,015 | Island | 0.008 | 0.55 | 2.57E-34 | 4.84E-30 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cg22783327 | FXYD1 | 19 | 35,633,258 | N_Shore | Body | 0.006 | 0.30 | 2.71E-34 | 4.84E-30 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cg06519422 | GABBR1 | 6 | 29,599,226 | N_Shore | Body | 0.004 | 0.46 | 2.82E-34 | 4.84E-30 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Top 20 significant differentially methylated CpGs associated with age in the fetal lung data set. P-values were adjusted by the Benjamini-Hochberg method to correct for multiple testing. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abbreviations: UCSC, The University of California Santa Cruz; Coef, regression coefficient - Adjusted mean difference (per day increase or decrease) in methylation with age. NA: un-annotated CpG site; CHR, chromosome; AveBeta, average beta; P, p-value. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the adult lung tissue (ALT) dataset, COPD subjects differed from subjects without COPD by time since quitting cigarette smoking (in months), LAA-950 and pack-years but did not differ by age (Table 1). We identified 2,217 (0.7%) significant aDMPs (FDR <0.05, Supplementary Table 2,Figure 1). Of those, 2,181 were relatively hyper-methylated and 36 were relatively hypo-methylated with increasing age and a maximum absolute effect size of 0.7% per year (Supplementary Figure 2B). These aDMPs were strongly enriched for transcription start sites (Hypergeometric P-Value=2.1x10-31). The top 20 significant age-associated DMPs were mostly located in CpG islands; their top associated genes included DLL3 and PRDM2 (Table 2B). Two sites, cg16867657 (regression coefficient: 0.004, FDR adjusted P=3.8x10-9) and cg24724428 (regression coefficient: 0.006, FDR adjusted P=3.8x10-9) annotated to ELOVL2 gene, a biomarker of age [25] and also the top gene based on effect size in the adult lung data (Supplementary Figure 2B).
Table 2B. Age-associated differential methylation in the adult lung tissue dataset.
| CG site | UCSC Gene | CHR | MAPINFO | Island | Gene context | Coef | AveBeta | P-Value | Adjusted P | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cg07640648 | DLL3 | 19 | 39,993,697 | Island | Body | 0.001 | 0.04 | 1.15E-14 | 2.00E-09 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cg26830108 | NA | 7 | 100,813,299 | N_Shelf | 0.002 | 0.07 | 7.02E-15 | 2.00E-09 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cg02650266 | NA | 4 | 147,558,239 | Island | 0.003 | 0.13 | 2.73E-14 | 2.34E-09 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cg05024939 | NA | 4 | 113,442,251 | N_Shore | 0.002 | 0.26 | 3.35E-14 | 2.34E-09 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cg23813012 | PRDM2 | 1 | 14,026,482 | Island | TSS1500 | 0.002 | 0.10 | 2.70E-14 | 2.34E-09 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cg05617798 | AURKB | 17 | 8,113,714 | Island | 5'UTR | 0.001 | 0.07 | 6.07E-14 | 2.61E-09 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cg21186299 | VGF | 7 | 100,808,810 | Island | 1stExon | 0.001 | 0.03 | 6.73E-14 | 2.61E-09 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cg23606718 | AMER3 | 2 | 131,513,927 | Island | 5'UTR | 0.003 | 0.24 | 5.61E-14 | 2.61E-09 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cg27320127 | KCNK12 | 2 | 47,798,396 | Island | TSS1500 | 0.003 | 0.22 | 4.54E-14 | 2.61E-09 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cg16477091 | PPM1E | 17 | 56,833,000 | Island | TSS1500 | 0.002 | 0.15 | 8.06E-14 | 2.82E-09 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cg10806820 | CELSR3 | 3 | 48,699,090 | Island | 1stExon | 0.003 | 0.22 | 9.47E-14 | 3.01E-09 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cg12373771 | CECR6 | 22 | 17,601,381 | Island | 1stExon | 0.003 | 0.22 | 1.25E-13 | 3.65E-09 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cg16867657 | ELOVL2 | 6 | 11,044,877 | Island | TSS1500 | 0.004 | 0.74 | 1.49E-13 | 3.76E-09 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cg24724428 | ELOVL2 | 6 | 11,044,888 | Island | TSS1500 | 0.006 | 0.26 | 1.50E-13 | 3.76E-09 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cg01763090 | OTUD7A | 15 | 31,775,406 | N_Shore | 3'UTR | 0.002 | 0.12 | 1.89E-13 | 4.40E-09 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cg15906794 | YBX2 | 17 | 7,197,963 | Island | TSS200 | 0.004 | 0.17 | 2.84E-13 | 6.22E-09 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cg02383785 | NA | 7 | 127,808,848 | Island | 0.003 | 0.22 | 3.68E-13 | 7.57E-09 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cg05991454 | NA | 4 | 147,558,435 | Island | 0.003 | 0.12 | 5.58E-13 | 1.08E-08 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cg07544187 | CILP2 | 19 | 19,651,235 | Island | Body | 0.004 | 0.15 | 6.05E-13 | 1.11E-08 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cg03036557 | GPC5 | 13 | 92,050,720 | N_Shore | TSS1500 | 0.002 | 0.07 | 1.79E-12 | 3.13E-08 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Top 20 significant and differentially methylated CpGs associated with age in the adult lung tissue dataset. P-values were adjusted by the Benjamini-Hochberg method to correct for multiple testing. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abbreviations: UCSC, The University of California Santa Cruz; Coef, regression coefficient - Adjusted mean difference (per year increase or decrease) in methylation with age. NA: un-annotated CpG site; CHR, chromosome; AveBeta, average beta; P, p-value. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the aDMPs identified in the adult lung dataset, 244 CpGs (11% of the differentially methylated loci) that mapped to 144 unique genes (13.7% of the unique differentially methylated genes) overlapped with the fetal lung age-EWAS (Supplementary Table 3). The corresponding findings from the analysis stratified by IUS-exposure and COPD status in fetal and adult lung datasets for these 244 CpGs have been included in Supplementary Table 3. In the fetal lung dataset, the effect estimates for 238 CpGs from the non-IUS-exposed and all 244 CpGs from the IUS-exposed samples only analysis were in the same direction to the effect estimates of the 244 overlapping aDMPs from the overall fetal lung analysis. In the ALT dataset, 243 CpGs from the non-COPD subjects only and all 244 CpGs from the COPD case-only analysis were in the same direction of effect to the effect estimates of the 244 overlapping aDMPs from the overall ALT analysis (Supplementary Table 3).
The top 20 annotated CpGs were associated with nine transcription factors: EVX1, HIF1A, ALX3, SATB2, PITX2, NKX2-4, ZIC1, ZIC2, BSX and are presented in Table 2C. Of those 244 CpGs, 215 had effect estimates in the same direction (210 hyper- and five hypo-methylated) including the CpG site cg16867657 mapped to the promoter of ELOVL2 gene. The methylation patterns for cg16867657 were progressively hyper-methylated with age for both the fetal and adult lung datasets (Supplementary Figure 3A, 3B).
Table 2C. Age-associated differential methylation in the fetal and adult lung tissue datasets.
| Fetal lung | Adult lung | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CG site | CHR | MAPINFO | UCSC Gene | Context | Avebeta | Coef | Adjusted P | AveBeta | Coef | Adjusted P | Direction | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cg22296612 | 6 | 15,457,699 | JARID2 | Body | 0.92 | 0.002 | 3.60E-15 | 0.99 | -0.0001 | 0.016 | +- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cg17110767 | 1 | 243,637,966 | SDCCAG8 | Body | 0.67 | 0.003 | 4.24E-13 | 0.97 | 0.001 | 0.014 | ++ | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cg20801476 | 7 | 27,281,465 | EVX1 | TSS1500 | 0.06 | 0.001 | 5.27E-13 | 0.24 | 0.001 | 0.048 | ++ | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cg20580088 | 14 | 62,161,583 | HIF1A | TSS1500 | 0.13 | 0.001 | 2.28E-12 | 0.28 | 0.002 | 0.012 | ++ | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cg17611674 | 10 | 8,094,431 | FLJ45983 | Body | 0.10 | 0.001 | 2.34E-12 | 0.38 | 0.002 | 0.020 | ++ | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cg24388061 | 8 | 141,249,678 | TRAPPC9 | Body | 0.73 | 0.002 | 7.82E-12 | 0.94 | 0.001 | 0.008 | ++ | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cg21595709 | 19 | 15,344,186 | EPHX3 | TSS1500 | 0.05 | 0.001 | 2.90E-11 | 0.21 | 0.001 | 0.039 | ++ | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cg00484358 | 1 | 110,610,995 | ALX3 | Body | 0.12 | 0.001 | 1.07E-10 | 0.38 | 0.001 | 0.039 | ++ | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cg27583307 | 2 | 200,320,750 | SATB2 | Body | 0.03 | 0.000 | 2.35E-10 | 0.11 | 0.001 | 0.049 | ++ | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cg03470772 | 4 | 85,503,328 | CDS1 | TSS1500 | 0.03 | 0.000 | 4.48E-10 | 0.26 | 0.002 | 0.028 | ++ | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cg20992114 | 4 | 111,542,825 | PITX2 | Body | 0.08 | 0.001 | 7.98E-10 | 0.28 | 0.001 | 0.002 | ++ | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cg07247419 | 20 | 21,376,484 | NKX2-4 | 3'UTR | 0.02 | 0.000 | 1.45E-09 | 0.24 | 0.002 | 0.007 | ++ | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cg22197050 | 2 | 63,276,183 | LOC100132215 | TSS1500 | 0.03 | 0.000 | 5.83E-09 | 0.27 | 0.002 | 0.000 | ++ | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cg06306198 | 3 | 147,128,998 | ZIC1 | Body | 0.05 | 0.001 | 1.73E-08 | 0.23 | 0.001 | 0.042 | ++ | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cg11814235 | 18 | 28,621,490 | DSC3 | Body | 0.02 | 0.000 | 1.97E-08 | 0.12 | 0.001 | 0.031 | ++ | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cg14614094 | 9 | 133,567,903 | EXOSC2 | TSS1500 | 0.36 | 0.001 | 3.80E-08 | 0.69 | 0.002 | 0.015 | ++ | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cg15110296 | 12 | 12,509,705 | LOH12CR1 | TSS1500 | 0.68 | -0.002 | 5.41E-08 | 0.26 | -0.003 | 0.042 | -- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cg18431640 | 13 | 100,637,191 | ZIC2 | Body | 0.03 | 0.000 | 1.45E-07 | 0.19 | 0.001 | 0.008 | ++ | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cg24719321 | 11 | 122,850,490 | BSX | Body | 0.02 | 0.000 | 1.53E-07 | 0.18 | 0.002 | 0.002 | ++ | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cg08376141 | 6 | 32,116,591 | PRRT1 | 3'UTR | 0.11 | 0.001 | 2.11E-07 | 0.53 | 0.003 | 0.003 | ++ | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Top 20 annotated and differentially methylated age-associated DMPs overlapping between fetal lung and the adult lung tissue dataset. P-values were adjusted by the Benjamini-Hochberg method and are sorted based on the discovery fetal lung dataset. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abbreviations: UCSC, The University of California Santa Cruz; Coef, regression coefficient - Adjusted mean difference (per day increase or decrease for fetal lung dataset and per year increase or decrease for adult lung tissue dataset) in methylation with age. NA: un-annotated CpG site; CHR, chromosome; AveBeta, average beta; P, p-value. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Considering aging may have a genetic component, we had further investigated the presence of methylation quantitative trait loci (mQTLs) among the overlapping 244 aDMPs using the previously published methylation lung tissue QTL results [26]. Sixty-three (25.8%) and 17 (7%) of the 244 aDMPs in both fetal and adult lung datasets overlapped with the 1,787 significant cis mQTLs (located within 1 Mb of a specific CpG site) and 133 significant trans mQTLs (located beyond 1 Mb of a specific CpG site or on different chromosomes) at an FDR < 0.05 (Supplementary Table 4) which provide evidence for genetically influenced aDMPs. Interestingly, among the overlap with cis-mQTLs, the top gene based on significance was FADS2; its associated polymorphisms modulate fatty acid metabolism [27] and influence asthma risk [28]. However, the smaller overlap with mQTLs suggests that majority of our age associations (67.2%) were not genetically driven.
The regional analysis in fetal and adult lung datasets resulted in 14,427 and 270 significant regions (FDR<0.05) respectively with an overlap of three regions by exact chromosomal coordinates and 878 regions (Supplementary Table 5) by overlapping genes. Two of those regions with exact overlap of chromosomal coordinates mostly mapped to small nucleolar RNAs (snoRNAs/SNORA) and small cajal body-specific RNAs (scaRNAs/SCARNA) family genes, while the third region could not be mapped to any genes.
Effect modification of age-associated methylation by smoke exposure and sex
In the fetal lung data, the interaction between gestational age and exposure to cotinine (continuous variable) resulted in 11,810 differentially methylated CpGs (P<0.05); none were robust to adjustment at an FDR of 5% (FDR<0.05) or less stringent threshold of 10% (FDR<0.10) but many passed at a nominal P-value of 0.05 (Supplementary Table 6). This is consistent with the modest findings from our prior IUS “main effects” analysis [29]. Interaction between gestational age and sex revealed three CpGs. relatively hyper-methylated with age in males compared to females (FDR<0.10, Supplementary Table 7).
In the adult lung data, the interaction of chronological age with time since smoking cessation resulted in one differentially methylated CpG site mapped to the DSCC1 gene (cg21745419; regression coefficient =3.3x10-6; FDR adjusted P=3.9x10-3). The interaction between age and pack-years resulted in 10 differentially methylated CpGs significant at an FDR threshold of 0.05 (Supplementary Table 8). One CpG site: cg10682155 mapped to the SIM2 gene and overlapped with the nominal age by exposure associations in fetal lung (Supplementary Table 7). Interaction of age with sex resulted in 47 significant differentially methylated sites (FDR<0.10, Supplementary Table 8); 21 of those CpG sites were also significant at an FDR threshold of 0.05. Interestingly, cg24724428 mapped to the ELOVL2 gene promoter and also demonstrated age-by-sex associations (regression coefficient=0.007; FDR adjusted P=0.06). This CpG was 10 bases upstream of the age-associated ELOVL2 CpG site cg16867657. These analyses demonstrated potential methylation effect modification with age by both sex and smoke exposure in fetal and ALT datasets.
CpGs associated with age are enriched in transcription factor pathways
Genes annotated to hyper-methylated aDMPs in both fetal and adult lung tissue datasets had the most significant enrichment for RNA polymerase II-specific DNA-binding transcription factor activity (FDR adjusted P=2.0x10-33; 52 genes; Supplementary Table 9,Figure 2A). Genes annotated to hypo-methylated aDMPs were mainly enriched (FDR<0.05, Figure 2B) for Cell Cycle (PRKCA, NCAPD3), oxidoreductase activity (ALDH4A1, PDIA6) and VEGFA-VEGFR2 signaling pathway (PRKCA, PDIA6), however this analysis may have been limited due to the small number of genes represented by few overlapping hypo-methylated aDMPs between both datasets. Most enriched biological processes in the overlapping aDMPs between fetal and ALT included terms related to development including embryonic organ morphogenesis, neurogenesis and growth delay. Two enriched wiki-pathways were identified: Neural Crest Differentiation annotated with five genes (ZIC1, HAND1, OLIG3, ZIC5, PAX3) and Mesodermal Commitment Pathway annotated with six genes (PITX2, ZIC2, HAND1, PAX6, ZIC5, SOX21).
Figure 2. Network visualization, functional enrichment and region-gene associations in both fetal and adult lung tissue datasets. Network clusters of the molecular function gene ontology terms and annotated pathways including reactome and wikiPathways were created using the gene symbols mapped to the significant and age-associated differentially methylated positions (DMPs) overlapping between fetal and adult lung datasets. (A) Hyper-methylated CpGs were mainly enriched in transcription factor DNA binding whereas (B) hypo-methylated CpGs were enriched in oxidoreductase activity. Size corresponds to the overlap of genes between the enriched terms and color corresponds to significance. The analysis for hypo-methylated CpGs was limited by few numbers of genes represented by few CpGs (C) Functional enrichment of age-associated hyper-methylated DMPs in both fetal and adult lung tissue datasets amongst differentially expressed genes in 54 GTEx tissues (x-axis) and –log10(P-value) on the y-axis. Tissues with significant gene enrichment (FDR<0.05) are highlighted by red bars and tissues with the highest enrichment amongst the downregulated and upregulated genes are highlighted by arrows (D) Region-Gene associations using chromosomal coordinates for the differentially methylated regions in fetal lung dataset (E) Adult lung tissue dataset. TSS: transcription start site.
The 125 genes with age associations in the same direction in both fetal and ALT datasets were further assessed for gene-based enrichment analysis and functional relevance in gene-sets using tissue-specific expression in 54 tissue types from the Genotype-Tissue Expression project (GTEx) v8 [30]. Among the tissue-specific gene-sets, the strongest enrichment for hyper-methylated CpGs was observed among the down-regulated genes in the lung; up-regulated genes were noted for brain regions but not for lung (Figure 2C, Supplementary Table 10). Among the curated gene-sets and transcription factor targets obtained from MsigDB, the strongest enrichment was for poly-comb regulated genes in human embryonic stem cells, predominantly H3K27me3 and transcription factor binding sites respectively (Supplementary Figure 4A, 4B). The most enriched transcription factor target gene-set included PAX6, HOXC4, FOXG1, SALL3, TBR1, DLX1, ZIC4, ZIC1, SHOX2, ATOH1, PITX2 and OLIG3 (Supplementary Figure 4C) with hyper-methylated CpGs in our findings. There was no tissue-specific or gene set enrichment observed for genes annotated to hypo-methylated CpGs, likely due to small numbers. Gene associations for the significant differentially methylated regions also had the most significant enrichment for RNA polymerase II transcription factor activity/sequence-specific DNA binding (Supplementary Table 11) with a significant percentage of those within 5kb of transcription start site for both fetal and ALT datasets (Figure 2D, 2E).
Measures of epigenetic age acceleration in fetal and adult lung tissues
We did not identify a large overlap between the 353 Horvath clock markers and our differentially methylated age EWAS associations. Of the 353 CpG clock markers, 91 markers existed within the fetal lung aDMPs and 17 within the adult lung aDMPs and two CpGs (cg12946225: HMG20B; cg23517605: TUBB2B) were common to all three comparisons. Our EWAS quality control processing pipeline filtered out some of those 353 clock markers, however the smaller overlap may also suggest a different subset of age associations captured between the models.
Among the fetal lung samples, chronological age was significantly positively correlated with the DNAmAge as expected (cor=0.76, P=3.6x10-16, Supplementary Figure 5A). Overall, the fetal lung sample ages appeared epigenetically accelerated with higher age estimates for DNA methylation age compared to chronological age (Table 1). However, IUS-exposure was associated with lower epigenetic age differences when compared to epigenetic age of unexposed samples after adjusting for available covariates, suggesting relative developmental delay related to IUS exposure (Estimate: -0.10; 95% CI: -0.19, -0.01; P=0.03; Table 3). In the multivariate regression model including age and other covariates, we did not detect statistical differences by sex although they were in the same direction of effect as in the ALT dataset (Table 3).
Table 3. Associations between epigenetic age acceleration and lung phenotypes; IUS-exposure and sex in fetal lung dataset and COPD status, sex, time since quitting (in months), pack-years and fraction of lung voxels with low attenuation areas at less than -950 Hounsfield Units (LAA-950) in the adult lung tissue dataset.
| Epigenetic clock metrics in fetal and adult lung tissues | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Age Acceleration | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Multivariate model predictors | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fetal Lung | Estimate (95% CI) | P-value | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| IUS-exposure | -0.10 (-0.19, -0.01) | 0.03 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sex | 0.03 (-0.07, 0.12) | 0.57 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Adult Lung | Estimate (95% CI) | P-value | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| COPD | 2.20 (-1.04, 5.44) | 0.18 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sex | 1.98 (0.13, 3.83) | 0.036 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| months-quit | -0.01 (-0.02, 0.004) | 0.21 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| pack-years | -0.01 (-0.05, 0.02) | 0.46 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LAA-950 | -1.94 (-9.30, 5.43) | 0.60 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Multivariate models were residualized for age and were additionally adjusted for potential confounders in both datasets. In fetal lung dataset, unexposed samples were used as reference compared to IUS-exposed samples; covariates included post-conception/gestational age (continuous) and sex (male or female; female as reference). In adult lung tissue dataset, subjects without COPD were used as reference compared to COPD subjects; covariates included chronological age, sex (male or female; female as reference), race (white, African-Americans and others), pack-years (smoke exposure, continuous), LAA-950 (marker for airway emphysema, continuous), months-quit, (time since quitting in months, continuous) and technical covariate sample plate. DNAmAge as output from Horvath clock (in years) was used for both datasets. Age acceleration was calculated as the difference between DNAmAge and chronological age. Significant P-Values are highlighted as bold. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abbreviations: CI, confidence interval. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Missing data: Time sine quitting data (months) was missing for 1 subject without COPD, fraction of lung voxels with low attenuation areas at less than -950 Hounsfield Units (LAA-950) was missing for 27 subjects without COPD and 28 COPD subjects. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the adult lung dataset, we observed significant positive correlation between chronological age and the DNAmAge (cor=0.74, P<2.2x10-16; Supplementary Figure 5B). The COPD cases showed a trend for accelerated aging compared to subjects without COPD (Estimate: 2.20; 95% CI: -1.04, 5.44; P=0.18, Table 3); however males demonstrated significant epigenetic age acceleration compared to females that stayed robust after adjustment with covariates in the multivariate model (Estimate: 1.98; 95% CI: 0.13, 3.83; P=0.036, Table 3).
Investigating smoking cessation behaviors, there was a suggestive trend for association between age acceleration and recent smoke cessation only within females compared to males in the multivariate model. The trend was not significant in males, however the effect estimates were in the same direction (Supplementary Table 12).
Discussion
Aging and age-associated epigenetic drift [31] in prenatal and postnatal life drive progressive and widespread methylation changes that can be captured by epigenetic clocks [16], however there is no clear gold standard [21]. Telomere shortening had long been considered a hallmark of biological aging, however recently weak correlation was found between telomere length and age-associated health outcomes [32]. With refinement in aging algorithms, ongoing efforts for precision health initiatives aim to identify better epigenetic biomarkers with predictive potential for obstructive lung disease, as these may facilitate primary interventions [33]. Our study importantly contributes to identifying age-associated patterns of differential methylation overlapping between early-life (fetal) and adulthood (adult lung) implicated in crucial developmental processes and demonstrates their effect modification by sex and smoke-exposure. This has never been examined before in lung tissue studies.
Rapid and considerable changes in methylation occur in early fetal life; therefore our finding of thousands of age-associated DMPs in fetal lung is not surprising. One of the most interesting and encouraging global findings was enrichment of hyper-methylated CpGs for transcription factor activity and down-regulated genes in the lung from GTEx gene-sets. Increased tissue-specific transcriptional variability has been associated with age, with DNA methylation playing an integral role in activating or silencing a gene mediated by transcription factor binding [34]. Evidence also suggests age-associated hypermethylation in whole blood to occur at chromatin promoter domains typical of transcriptional repression in nearby neural genes [35] and those that are involved in DNA binding and transcriptional regulation [36]. Aberrant hypermethylation and silencing of genes required for maintenance of a differentiated state has been observed in murine lung development and lung cancer [37]. A 2012 healthy aging study [38] pointed out that the age-associated DMPs and DMRs that are often activated or deregulated early in life hinted towards developmental defects that may not necessarily represent healthy aging in later life and cause a wide range of detrimental health outcomes. As an example, one of the several transcription factors that we mentioned was ZIC1. The tissue-specific transcription factor ZIC1 and its family functions by binding to enhancer regions in the developing brain and was identified as having a crucial regulatory role in neuronal differentiation and age-related Alzheimer's disease [39]. When looking specifically at region-overlap, the majority of those genes included snoRNAs/scaRNAs. These non-coding RNAs have gained substantial interest lately due to their clinical relevance in various pathologies including lung cancer, host antiviral responses and their regulatory role in RNA modifications, splicing and telomerase activity [40]. Moreover, it was reassuring that our overlapping age-associated DMRs between both fetal and adult lung tissue datasets were also enriched in DNA-binding transcription factor activity with common gene-sets, which may represent regions of regulatory potential as well as targets of epigenetic therapy. Of course, functional transcription factor binding can only be confirmed via experimental validation. However these results do suggest that methylation changes associated with aging and environmentally mediated exposures throughout life may impact biological processes and pathways crucial for growth, development and immune system regulation during the life course. Considering directionality of effect, most of our adult EWAS findings between both fetal and adult lung datasets were hyper-methylated with age which is in line with the previous findings [38] pointing towards the methylation hotspots that are consistently altered with age-dependent or age-related phenotypes.
Age associated epigenetic variation may additionally reveal genes further disrupted in age associated lung diseases such as COPD. In our fetal lung aDMPs, we found previously discussed differentially methylated age-associations identified in fetal brain tissue [13] including the Wnt antagonist SFRP1 known to be differentially methylated in adults with asthma [41] and previously associated with emphysema [42], nuclear receptor gene NR4A2 crucial for neurogenesis and SHANK2 implicated in neurodevelopmental disorders such as autism and severe asthma [13, 43]. ELOVL2 is a consistently identified biomarker for aging [12] further supported by our finding of association of the age-related ELOVL2 gene and the rapid hypermethylation of its promoter cg16867657 [25, 44]. Interestingly, we also identified an age-by-sex association for the ELOVL2 gene, at another nearby CpG site: cg24724428; both these sites were significantly correlated with age in the EWAS Atlas and in the majority of tissues [44].
Age associated enrichment of hypo-methylated sites characterized by methylation protein binding, oxido-reductase and aldehyde dehydrogenase activity while limited with few CpGs in our study could point to oxidative stress that can cause susceptibility to inflammatory disorders of the airways such as asthma and COPD. Variable methylation and expression changes have previously linked aging, COPD [45] and idiopathic pulmonary fibrosis (IPF) [46]. Of note, genes in VEGFA-VEGFR2 signaling mapped to hypo-methylated CpGs. The vascular endothelial growth factor-A and its family is crucial for endothelial cell survival and angiogenesis and its components are known biomarkers for asthma-COPD overlap syndrome [47]. One of the blood-based studies in lung tissue associated smoking with site-specific hypo-methylation [48]. The age-associated sites modified by smoke exposure and smoking cessation may further attenuate the risk of age-related lung diseases such as COPD and IPF or may point to reversed methylation signatures by smoking cessation over time for fetal origins of lung disease and susceptibility to other developmental or neurological disorders triggered in early life. There is also evidence that imbalance in the redox potential mediates inflammation, airflow limitation and airway remodeling in asthma and COPD [49]. Cigarette smoking is known to cause oxidative stress, disrupting the vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR) signaling and may promote emphysema [49]. These findings provide mechanistic insights into lung tissue-specific signatures of hypo- and hyper-methylation with age, pointing to a sensitive transcriptional regulation mediated by DNA methylation modifications during in-utero periods of developmental plasticity and later life.
We further examined epigenetic age acceleration or deceleration during the critical prenatal exposures and in later life. Our study highlighted epigenetic clock deceleration in IUS-exposed compared to unexposed samples. Prenatal exposure to hypoxic conditions has been associated with epigenetic age deceleration [50], alterations in immune and inflammatory responses, developmental delay and cognitive decline in later life [51]. In ALT, we observed age acceleration in males compared to females. This is in line with previously reported age acceleration in males over females corresponding with higher all-cause male mortality [12, 23, 51]. We also observed a suggestive trend in ALT for more recent smoking driving epigenetic age acceleration suggesting that smoking cessation could improve respiratory and lung health through modulation of lung aging pathways, a finding of potential public health relevance further supporting efforts to curb inhalational exposures starting early in life.
These findings suggest two plausible aging mechanisms [22]: (i) disruption to the aging processes may begin before birth, and (ii) certain prenatal exposures might increase/decrease the disease risks through perturbations in aging pathways as a defense or adaptation mechanism. In accordance with this hypothesis, decreased epigenetic age was associated with longevity in supercentenarians and their offspring [52] but also cerebroplacental ratio, a marker for fetal adaption to hypoxic conditions and adverse pregnancy outcome [50].
We acknowledge that our study also has limitations including the sample sizes of the lung datasets, paucity of longitudinal lung tissue data, limited phenotype data including race, geography, socioeconomic status in the fetal lung dataset and potential residual confounding by cellular heterogeneity associated with the lung samples even after surrogate variable adjustment. Evidence of high genomic inflation, despite adjusting for confounders as we have in this study, has also been observed and discussed frequently in other age EWAS studies and in principle could be used as a marker of development and biological age [11, 53, 54]. Moreover, limited association in fetal and adult lung tissue with the epigenetic clock metrics could be due to lack of a true association or the consideration that a lung specific clock would perform better, given the richness of the age associated EWAS findings. However, investigating age-associated methylation signatures using a robust analytical framework, in unrelated fetal and adult lung tissue samples with a broader age range including critical stages of development as well as adulthood, strengthens our study. Of note, it is unlikely that one particular omic-type or few genetic variants could lead to complex diseases of lung. Therefore, integrative omics analyses with larger sample sizes would mostly support future sensitivity or sex-stratified analyses and contribute to the greatest extent in identifying causal genes and pathways.
In summary, our findings point to age-related differential methylation that may serve as a starting point for similar future studies to advance our understanding of age-associated epigenetic programming and aid development of more sensitive lung based epigenetic age estimator. From a public health standpoint, considering overlapping developmental and aging pathways as potential targets for future interventions early in life may have relevance to curb the incidence of complex chronic diseases with the aging of the global population. Our study combines aging and epigenetic signatures and may constitute a system to promote lung health and longevity by evaluating age-modifying interventions across the life course.
Materials and Methods
Study samples
Fetal lung DNA samples (n=78, 42 exposed to in utero maternal cigarette smoke (IUS), 36 non-IUS-exposed) were isolated from discarded tissue from 57-122 days of gestation as previously described [29, 55]. We performed genome-wide methylation profiling on these samples using the Illumina HumanMethylation450 BeadChip. Fetal sex was confirmed using unique Y chromosome microarray probes and verified using X and Y chromosome methylation. IUS exposure was assessed by measuring placental cotinine concentrations [56]. Exposure was treated as a dichotomous variable (1/0 with 1=exposed), with levels of cotinine < 7.5 ng/g considered as unexposed and levels of cotinine > 7.5 ng/g as exposed, though we also assessed the continuous cotinine variable. Approval was obtained from the Partners Human Research Committee Institutional Review Board in Boston, MA.
We used our previously published [57] adult lung tissue (ALT) dataset, from the Adult Lung Tissue study (n=160; 114 COPD cases, 46 subjects without COPD) to investigate age-associated differential methylation in adulthood. Genetic data was available for a subset of these samples. This led to removal of eight samples from the fetal lung dataset and 11 samples from the ALT dataset for whom we could not calculate ancestry principal components due to unavailability of the data. This applied to all the epigenome-wide association (EWAS) models.
Epigenome-wide age association and statistical analyses
The proportion of DNA methylation at any CpG site reported as the Illumina beta (β)-value is defined as the ratio between methylated signal intensity and total probe signal intensity of methylated and un-methylated signal. A β-value ranges between 0 and 1 where 0 is considered an un-methylated CpG site and a value approaching 1 is considered a completely methylated CpG site. For biological interpretation purposes, we used beta-scale for all models [58]. Normalization and preprocessing were performed in Bioconductor [59] package Minfi [60]. We evaluated site based differential methylation (outcome) by age in both fetal lung and adult lung datasets with linear regression using limma [61] with correction for multiple testing using Benjamini-Hochberg method. We accounted for the following available covariates from the fetal lung data: IUS-exposure to cotinine (0: unexposed as reference, 1: exposed subjects) and sex (male/female with female as reference) and sample plate and sentrix position as technical covariates. Correcting for sentrix position accounts for the positional effects of the samples on the array [62]. For adult lung data, we included the following covariates: COPD disease status (cases/subjects without COPD as reference), sex (male/female as reference), race (white as reference versus black and others), pack-years (continuous) and sample plate as a technical covariate. The models evaluating age-associated differential methylation were further tested with interaction terms to assess effect modification by smoke exposure and sex. Ancestry composition was estimated from genetic data using the TRACE program (fasT and Robust Ancestry Coordinate Estimation) as implemented in the LASER package: (http://csg.sph.umich.edu/chaolong/LASER/) [63]. For the fetal and ALT datasets, we adjusted for genetic confounding using the first three (12.3%) and two (8.3%) principal components (PCs) respectively that explained most variability in the data. PCs did not reveal any confounding by row and column for the ALT dataset so sentrix position was not included in the model. Additionally, we accounted for unknown technical confounders in the fetal lung dataset such as observed due to cell-type heterogeneity using supervised version of surrogate variable analysis (s-sva) [64].
Differentially methylated positions (DMPs) were categorized as hyper- or hypo-methylated with a unit increase in chronological age (per day for fetal lung and per year for adult lung dataset). We further evaluated age-related differential methylation for effect modification and included interaction terms of age with IUS-exposure (categorical variable), cotinine levels (continuous variable) and sex in the fetal lung dataset and pack-years, sex, COPD, time since quitting/smoking cessation (in months) and fraction of lung voxels with low attenuation areas at less than -950 Hounsfield Units (LAA-950) to assess emphysema in the adult lung dataset. For main effects, we used a False Discovery Rate (FDR) of less than or equal to 0.05 and for interaction results, we relaxed thresholds for exploration and used an FDR of 10% (FDR<0.10). CpG sites were mapped to genes within which they were located using Human Genome build: GRCh37/hg19 and Bioconductor annotation package: IlluminaHuman Methylation450kanno.ilmn12.hg19 [65] and their gene context annotations were provided. If the CpG sites were not mapped to a gene, only their CpG island annotations were provided. We identified the overlapping age-associated differentially methylated positions/CpGs (aDMPs) between fetal and ALT datasets at probe level and at an FDR < 0.05. As a sensitivity analysis, we additionally evaluated the age associations in fetal and ALT datasets after stratifying by IUS-exposure and COPD status respectively. Considering aging may have a genetic component, we further investigated the presence of methylation quantitative trait loci (mQTLs) among these aDMPs using the previously published methylation lung tissue QTL results [26].
Region-based analyses was performed using the kernel smoothing method DMRCate [66]. Differentially methylated regions (DMRs) were calculated from log transformed CpG values (M-values) and defined as regions with at least two significant sites separated by a maximal distance of 1000 base pairs at an FDR of less than or equal to 0.05.
Enrichment of disease associations and pathway analysis
Functional gene-set enrichment [30] and visualization of tissue-specific gene clusters was performed for significant aDMPs overlapping between fetal and ALT datasets using FUMA [30]. Unique gene symbols were mapped to Entrez IDs using Bioconductor package org.Hs.eg.db [67]. Network representation of clusters for the enriched gene ontology terms and pathways was performed using AutoAnnotate [68] and EnrichmentMap [69] apps in Cytoscape 3.7.1 [70]. Biological processes and pathways connected by edges were retained in the final network. Over-representation and pathway analysis of genes annotated to overlapping sites and regions was performed using gProfiler2 [71] package in R and Genomic Regions Enrichment of Annotations Tool (GREAT) [72] version 4.0.4 (http://great.stanford.edu/public/html/) respectively.
DNAmAge and measures of epigenetic age acceleration
The Horvath clock [16] captures DNA methylation changes in chronological age using multiple tissue types and implies the epigenetic patterns from birth to the current age and included lung and fetal tissues during algorithm development. Therefore, we chose the Horvath clock method to determine the epigenetic age (DNAmAge) (http://labs.genetics.ucla.edu/horvath/dnamage/) [16] for the complete set of fetal (n=78) and adult lung samples (n=160) and additionally investigated differential methylation of the 353 CpG markers that form the aging clock. We computed two methylation-based age acceleration measures: age acceleration difference (epigenetic age – chronological age) and residual (linear regressing DNA methylation age on chronological age). Using age acceleration difference, we tested associations with IUS-exposure in fetal lung, and lung phenotypes in ALT. For all regression models, chronological age was included as a covariate [16]. To keep the units comparable to the chronological age in adult lung, post-conception age (in days) in fetal lung dataset was converted to a negative chronological age (in years) implying before birth: Chronological Age (in years) = Post Conception Age – (9*30)/365. In ALT dataset, correlation of epigenetic age acceleration with time since smoke cessation/quitting (in months) and LAA-950 was performed using Pearson correlation test. A positive difference between calculated epigenetic age and chronological age was considered accelerated aging and a negative difference decelerated aging.
Ethics approval and consent to participate
Institutional Review Board approval was obtained at the three centers (Brigham and Women’s Hospital (Boston, MA), St. Elizabeth’s Hospital (Boston, MA), and Temple University Hospital (Philadelphia, PA)) for adult lung tissue dataset. Human fetal lung tissues were obtained from two NICHD-supported tissue retrieval programs at the University of Washington Center for Birth Defects Research (Seattle, WA) and the University of Maryland Brain and Tissue Bank for Developmental Disorders (Baltimore, MD). Approval was obtained from the Partners Human Research Committee Institutional Review Board at Brigham and Women’s Hospital in Boston, MA who declared the use of these tissues non-human subject research (2010-P-002399). Written informed consent was obtained from all participants. Our research was performed in accordance with the principles of the Helsinki Declaration.
Supplementary Materials
Supplementary Figures
Supplementary Table 1
Supplementary Table 2
Supplementary Table 3
Supplementary Table 4
Supplementary Table 5
Supplementary Table 6
Supplementary Table 7
Supplementary Table 8
Supplementary Table 9
Supplementary Table 10
Supplementary Table 11
Supplementary Table 12
Abbreviations
IUS: in-utero-smoke; COPD: Chronic Obstructive Pulmonary Disease; GTEx: Genotype-Tissue-Expression Project; UCSC: The University of California Santa Cruz; CHR: chromosome; FDR: false discovery rate; P: P-value; DNA: Deoxyribonucleic acid; RNA: Ribonucleic acid; ALT: adult lung tissue; LAA-950: fraction of lung voxels with low attenuation areas at less than -950 Hounsfield Units; aDMPs: age-associated differentially methylated positions; DMRs: differentially methylated regions; TRACE: fasT and Robust Ancestry Coordinate Estimation; PCs: principal components; sva: surrogate variable analysis; GREAT: Genomic Regions Enrichment of Annotations Tool; DNAmAge: DNA methylation age; EWAS: epigenome-wide association study; mQTLs: methylation quantitative trait loci; SNORA/snoRNAs: small nucleolar RNAs; scaRNAs/SCARNA: small cajal body-specific RNAs; MSigDB: The Molecular Signatures Database; IPF: idiopathic pulmonary fibrosis; VEGFA-VEGFR2: Vascular Endothelial Growth Factor A-Vascular endothelial growth factor receptor 2.
Author Contributions
Conceptualization of the research, DLD and PK; methodology, PK, DLD; validation, PK, JDM. Formal statistical analysis, PK; resources and funding acquisition, STW, DLD; data curation, PK, JDM; writing—original draft preparation, PK; writing—review and editing, PK, JDM, DLD, STW, CAV, EKS, KGT; supervision, STW, JDM, DLD.
Conflicts of Interest
STW has received royalties from UpToDate. EKS received grant support from GlaxoSmithKline and Bayer. DLD reports grant support from Novartis and Bayer. PK, JDM, ATK, CAV and KGT report no conflict of interest.
Funding
This project was supported by the P01HL132825, P01HL114501, K25HL136846, R21HL107927 and R01HL097144 from NIH/NHLBI, and the Alpha-1 Foundation Research Grant.
References
- 1. Jones MJ, Goodman SJ, Kobor MS. DNA methylation and healthy human aging. Aging Cell. 2015; 14:924–32. https://doi.org/10.1111/acel.12349 [PubMed]
- 2. Ziller MJ, Gu H, Müller F, Donaghey J, Tsai LT, Kohlbacher O, De Jager PL, Rosen ED, Bennett DA, Bernstein BE, Gnirke A, Meissner A. Charting a dynamic DNA methylation landscape of the human genome. Nature. 2013; 500:477–81. https://doi.org/10.1038/nature12433 [PubMed]
- 3. Vaiserman A. Developmental tuning of epigenetic clock. Front Genet. 2018; 9:584. https://doi.org/10.3389/fgene.2018.00584 [PubMed]
- 4. Unnikrishnan A, Freeman WM, Jackson J, Wren JD, Porter H, Richardson A. The role of DNA methylation in epigenetics of aging. Pharmacol Ther. 2019; 195:172–85. https://doi.org/10.1016/j.pharmthera.2018.11.001 [PubMed]
- 5. Zhang W, Qu J, Liu GH, Belmonte JC. The ageing epigenome and its rejuvenation. Nat Rev Mol Cell Biol. 2020; 21:137–50. https://doi.org/10.1038/s41580-019-0204-5 [PubMed]
- 6. Tobi EW, Goeman JJ, Monajemi R, Gu H, Putter H, Zhang Y, Slieker RC, Stok AP, Thijssen PE, Müller F, van Zwet EW, Bock C, Meissner A, et al. DNA methylation signatures link prenatal famine exposure to growth and metabolism. Nat Commun. 2014; 5:5592. Erratum in: Nat Commun. 2015; 6:7740. https://doi.org/10.1038/ncomms6592 [PubMed]
- 7. Savran O, Ulrik CS. Early life insults as determinants of chronic obstructive pulmonary disease in adult life. Int J Chron Obstruct Pulmon Dis. 2018; 13:683–93. https://doi.org/10.2147/COPD.S153555 [PubMed]
- 8. Xiao FH, Wang HT, Kong QP. Dynamic DNA methylation during aging: a “Prophet” of age-related outcomes. Front Genet. 2019; 10:107. https://doi.org/10.3389/fgene.2019.00107 [PubMed]
- 9. Cui D, Xu X. DNA methyltransferases, DNA methylation, and age-associated cognitive function. Int J Mol Sci. 2018; 19:1315. https://doi.org/10.3390/ijms19051315 [PubMed]
- 10. Merid SK, Novoloaca A, Sharp GC, Küpers LK, Kho AT, Roy R, Gao L, Annesi-Maesano I, Jain P, Plusquin M, Kogevinas M, Allard C, Vehmeijer FO, et al. Epigenome-wide meta-analysis of blood DNA methylation in newborns and children identifies numerous loci related to gestational age. Genome Med. 2020; 12:25. https://doi.org/10.1186/s13073-020-0716-9 [PubMed]
- 11. McCartney DL, Zhang F, Hillary RF, Zhang Q, Stevenson AJ, Walker RM, Bermingham ML, Boutin T, Morris SW, Campbell A, Murray AD, Whalley HC, Porteous DJ, et al. An epigenome-wide association study of sex-specific chronological ageing. Genome Med. 2019; 12:1. https://doi.org/10.1186/s13073-019-0693-z [PubMed]
- 12. Tajuddin SM, Hernandez DG, Chen BH, Noren Hooten N, Mode NA, Nalls MA, Singleton AB, Ejiogu N, Chitrala KN, Zonderman AB, Evans MK. Novel age-associated DNA methylation changes and epigenetic age acceleration in middle-aged African Americans and Whites. Clin Epigenetics. 2019; 11:119. https://doi.org/10.1186/s13148-019-0722-1 [PubMed]
- 13. Spiers H, Hannon E, Schalkwyk LC, Smith R, Wong CC, O’Donovan MC, Bray NJ, Mill J. Methylomic trajectories across human fetal brain development. Genome Res. 2015; 25:338–52. https://doi.org/10.1101/gr.180273.114 [PubMed]
- 14. Bonder MJ, Kasela S, Kals M, Tamm R, Lokk K, Barragan I, Buurman WA, Deelen P, Greve JW, Ivanov M, Rensen SS, van Vliet-Ostaptchouk JV, Wolfs MG, et al. Genetic and epigenetic regulation of gene expression in fetal and adult human livers. BMC Genomics. 2014; 15:860. https://doi.org/10.1186/1471-2164-15-860 [PubMed]
- 15. Hannum G, Guinney J, Zhao L, Zhang L, Hughes G, Sadda S, Klotzle B, Bibikova M, Fan JB, Gao Y, Deconde R, Chen M, Rajapakse I, et al. Genome-wide methylation profiles reveal quantitative views of human aging rates. Mol Cell. 2013; 49:359–67. https://doi.org/10.1016/j.molcel.2012.10.016 [PubMed]
- 16. Horvath S. DNA methylation age of human tissues and cell types. Genome Biol. 2013; 14:R115. https://doi.org/10.1186/gb-2013-14-10-r115 [PubMed]
- 17. Bohlin J, Håberg SE, Magnus P, Reese SE, Gjessing HK, Magnus MC, Parr CL, Page CM, London SJ, Nystad W. Prediction of gestational age based on genome-wide differentially methylated regions. Genome Biol. 2016; 17:207. https://doi.org/10.1186/s13059-016-1063-4 [PubMed]
- 18. Levine ME, Lu AT, Quach A, Chen BH, Assimes TL, Bandinelli S, Hou L, Baccarelli AA, Stewart JD, Li Y, Whitsel EA, Wilson JG, Reiner AP, et al. An epigenetic biomarker of aging for lifespan and healthspan. Aging (Albany NY). 2018; 10:573–91. https://doi.org/10.18632/aging.101414 [PubMed]
- 19. Horvath S, Oshima J, Martin GM, Lu AT, Quach A, Cohen H, Felton S, Matsuyama M, Lowe D, Kabacik S, Wilson JG, Reiner AP, Maierhofer A, et al. Epigenetic clock for skin and blood cells applied to hutchinson gilford progeria syndrome and ex vivo studies. Aging (Albany NY). 2018; 10:1758–75. https://doi.org/10.18632/aging.101508 [PubMed]
- 20. Youn A, Wang S. The MiAge calculator: a DNA methylation-based mitotic age calculator of human tissue types. Epigenetics. 2018; 13:192–206. https://doi.org/10.1080/15592294.2017.1389361 [PubMed]
- 21. Bell CG, Lowe R, Adams PD, Baccarelli AA, Beck S, Bell JT, Christensen BC, Gladyshev VN, Heijmans BT, Horvath S, Ideker T, Issa JJ, Kelsey KT, et al. DNA methylation aging clocks: challenges and recommendations. Genome Biol. 2019; 20:249. https://doi.org/10.1186/s13059-019-1824-y [PubMed]
- 22. Javed R, Chen W, Lin F, Liang H. Infant’s DNA methylation age at birth and epigenetic aging accelerators. Biomed Res Int. 2016; 2016:4515928. https://doi.org/10.1155/2016/4515928 [PubMed]
- 23. Simpkin AJ, Howe LD, Tilling K, Gaunt TR, Lyttleton O, McArdle WL, Ring SM, Horvath S, Smith GD, Relton CL. The epigenetic clock and physical development during childhood and adolescence: longitudinal analysis from a UK birth cohort. Int J Epidemiol. 2017; 46:549–58. https://doi.org/10.1093/ije/dyw307 [PubMed]
- 24. Li X, Ploner A, Wang Y, Magnusson PK, Reynolds C, Finkel D, Pedersen NL, Jylhävä J, Hägg S. Longitudinal trajectories, correlations and mortality associations of nine biological ages across 20-years follow-up. Elife. 2020; 9:e51507. https://doi.org/10.7554/eLife.51507 [PubMed]
- 25. Garagnani P, Bacalini MG, Pirazzini C, Gori D, Giuliani C, Mari D, Di Blasio AM, Gentilini D, Vitale G, Collino S, Rezzi S, Castellani G, Capri M, et al. Methylation of ELOVL2 gene as a new epigenetic marker of age. Aging Cell. 2012; 11:1132–34. https://doi.org/10.1111/acel.12005 [PubMed]
- 26. Morrow JD, Glass K, Cho MH, Hersh CP, Pinto-Plata V, Celli B, Marchetti N, Criner G, Bueno R, Washko G, Choi AM, Quackenbush J, Silverman EK, DeMeo DL. Human lung DNA methylation quantitative trait loci colocalize with chronic obstructive pulmonary disease genome-wide association loci. Am J Respir Crit Care Med. 2018; 197:1275–84. https://doi.org/10.1164/rccm.201707-1434OC [PubMed]
- 27. Koletzko B, Reischl E, Tanjung C, Gonzalez-Casanova I, Ramakrishnan U, Meldrum S, Simmer K, Heinrich J, Demmelmair H. FADS1 and FADS2 polymorphisms modulate fatty acid metabolism and dietary impact on health. Annu Rev Nutr. 2019; 39:21–44. https://doi.org/10.1146/annurev-nutr-082018-124250 [PubMed]
-
28.
Sharma S, Zhou X, Thibault DM, Himes BE, Liu A, Szefler SJ, Strunk R, Castro M, Hansel NN, Diette GB, Vonakis BM, Adkinson NF
Jr , Avila L, et al. A genome-wide survey of CD4(+) lymphocyte regulatory genetic variants identifies novel asthma genes. J Allergy Clin Immunol. 2014; 134:1153–62. https://doi.org/10.1016/j.jaci.2014.04.011 [PubMed] - 29. Kachroo P, Morrow JD, Kho AT, Vyhlidal CA, Silverman EK, Weiss ST, Tantisira KG, DeMeo DL. Co-methylation analysis in lung tissue identifies pathways for fetal origins of COPD. Eur Respir J. 2020; 56:1902347. https://doi.org/10.1183/13993003.02347-2019 [PubMed]
- 30. Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping and annotation of genetic associations with FUMA. Nat Commun. 2017; 8:1826. https://doi.org/10.1038/s41467-017-01261-5 [PubMed]
- 31. Li Y, Tollefsbol TO. Age-related epigenetic drift and phenotypic plasticity loss: implications in prevention of age-related human diseases. Epigenomics. 2016; 8:1637–51. https://doi.org/10.2217/epi-2016-0078 [PubMed]
- 32. Marioni RE, Harris SE, Shah S, McRae AF, von Zglinicki T, Martin-Ruiz C, Wray NR, Visscher PM, Deary IJ. The epigenetic clock and telomere length are independently associated with chronological age and mortality. Int J Epidemiol. 2018; 45:424–32. https://doi.org/10.1093/ije/dyw041 [PubMed]
- 33. Gillespie SL, Hardy LR, Anderson CM. Patterns of DNA methylation as an indicator of biological aging: State of the science and future directions in precision health promotion. Nurs Outlook. 2019; 67:337–44. https://doi.org/10.1016/j.outlook.2019.05.006 [PubMed]
- 34. Yin Y, Morgunova E, Jolma A, Kaasinen E, Sahu B, Khund-Sayeed S, Das PK, Kivioja T, Dave K, Zhong F, Nitta KR, Taipale M, Popov A, et al. Impact of cytosine methylation on DNA binding specificities of human transcription factors. Science. 2017; 356:eaaj2239. https://doi.org/10.1126/science.aaj2239 [PubMed]
- 35. Rakyan VK, Down TA, Maslau S, Andrew T, Yang TP, Beyan H, Whittaker P, McCann OT, Finer S, Valdes AM, Leslie RD, Deloukas P, Spector TD. Human aging-associated DNA hypermethylation occurs preferentially at bivalent chromatin domains. Genome Res. 2010; 20:434–39. https://doi.org/10.1101/gr.103101.109 [PubMed]
- 36. Johansson A, Enroth S, Gyllensten U. Continuous aging of the human DNA methylome throughout the human lifespan. PLoS One. 2013; 8:e67378. https://doi.org/10.1371/journal.pone.0067378 [PubMed]
- 37. Helman E, Naxerova K, Kohane IS. DNA hypermethylation in lung cancer is targeted at differentiation-associated genes. Oncogene. 2012; 31:1181–88. https://doi.org/10.1038/onc.2011.307 [PubMed]
- 38. Bell JT, Tsai PC, Yang TP, Pidsley R, Nisbet J, Glass D, Mangino M, Zhai G, Zhang F, Valdes A, Shin SY, Dempster EL, Murray RM, et al, and MUTHER Consortium. Epigenome-wide scans identify differentially methylated regions for age and age-related phenotypes in a healthy ageing population. PLoS Genet. 2012; 8:e1002629. https://doi.org/10.1371/journal.pgen.1002629 [PubMed]
- 39. Zhao J, Cheng F, Jia P, Cox N, Denny JC, Zhao Z. An integrative functional genomics framework for effective identification of novel regulatory variants in genome-phenome studies. Genome Med. 2018; 10:7. https://doi.org/10.1186/s13073-018-0513-x [PubMed]
- 40. Mourksi NE, Morin C, Fenouil T, Diaz JJ, Marcel V. snoRNAs offer novel insight and promising perspectives for lung cancer understanding and management. Cells. 2020; 9:541. https://doi.org/10.3390/cells9030541 [PubMed]
- 41. Gunawardhana LP, Gibson PG, Simpson JL, Benton MC, Lea RA, Baines KJ. Characteristic DNA methylation profiles in peripheral blood monocytes are associated with inflammatory phenotypes of asthma. Epigenetics. 2014; 9:1302–16. https://doi.org/10.4161/epi.33066 [PubMed]
- 42. Qu J, Yue L, Gao J, Yao H. Perspectives on Wnt signal pathway in the pathogenesis and therapeutics of chronic obstructive pulmonary disease. J Pharmacol Exp Ther. 2019; 369:473–80. https://doi.org/10.1124/jpet.118.256222 [PubMed]
- 43. Liao SY, Linderholm AL, Yoneda KY, Kenyon NJ, Harper RW. Airway transcriptomic profiling after bronchial thermoplasty. ERJ Open Res. 2019; 5:00123–2018. https://doi.org/10.1183/23120541.00123-2018 [PubMed]
- 44. Bacalini MG, Deelen J, Pirazzini C, De Cecco M, Giuliani C, Lanzarini C, Ravaioli F, Marasco E, van Heemst D, Suchiman HE, Slieker R, Giampieri E, Recchioni R, et al. Systemic age-associated DNA hypermethylation of ELOVL2 gene: in vivo and in vitro evidences of a cell replication process. J Gerontol A Biol Sci Med Sci. 2017; 72:1015–23. https://doi.org/10.1093/gerona/glw185 [PubMed]
- 45. Du X, Yuan L, Wu M, Men M, He R, Wang L, Wu S, Xiang Y, Qu X, Liu H, Qin X, Hu C, Qin L, Liu C. Variable DNA methylation of aging-related genes is associated with male COPD. Respir Res. 2019; 20:243. https://doi.org/10.1186/s12931-019-1215-7 [PubMed]
- 46. Aquino-Gálvez A, González-Ávila G, Jiménez-Sánchez LL, Maldonado-Martínez HA, Cisneros J, Toscano-Marquez F, Castillejos-López M, Torres-Espíndola LM, Velázquez-Cruz R, Rodríguez VHO, Flores-Soto E, Solís-Chagoyán H, Cabello C, et al. Dysregulated expression of hypoxia-inducible factors augments myofibroblasts differentiation in idiopathic pulmonary fibrosis. Respir Res. 2019; 20:130. https://doi.org/10.1186/s12931-019-1100-4 [PubMed]
- 47. Ding Q, Sun S, Zhang Y, Tang P, Lv C, Ma H, Yu Y, Xu S, Deng Z. Serum IL-8 and VEGFA are two promising diagnostic biomarkers of Asthma-COPD overlap syndrome. Int J Chron Obstruct Pulmon Dis. 2020; 15:357–65. https://doi.org/10.2147/COPD.S233461 [PubMed]
- 48. Stueve TR, Li WQ, Shi J, Marconett CN, Zhang T, Yang C, Mullen D, Yan C, Wheeler W, Hua X, Zhou B, Borok Z, Caporaso NE, et al. Epigenome-wide analysis of DNA methylation in lung tissue shows concordance with blood studies and identifies tobacco smoke-inducible enhancers. Hum Mol Genet. 2017; 26:3014–27. https://doi.org/10.1093/hmg/ddx188 [PubMed]
- 49. Sundar IK, Yao H, Rahman I. Oxidative stress and chromatin remodeling in chronic obstructive pulmonary disease and smoking-related diseases. Antioxid Redox Signal. 2013; 18:1956–71. https://doi.org/10.1089/ars.2012.4863 [PubMed]
- 50. Palma-Gudiel H, Eixarch E, Crispi F, Morán S, Zannas AS, Fañanás L. Prenatal adverse environment is associated with epigenetic age deceleration at birth and hypomethylation at the hypoxia-responsive EP300 gene. Clin Epigenetics. 2019; 11:73. https://doi.org/10.1186/s13148-019-0674-5 [PubMed]
- 51. Simpkin AJ, Hemani G, Suderman M, Gaunt TR, Lyttleton O, Mcardle WL, Ring SM, Sharp GC, Tilling K, Horvath S, Kunze S, Peters A, Waldenberger M, et al. Prenatal and early life influences on epigenetic age in children: a study of mother-offspring pairs from two cohort studies. Hum Mol Genet. 2016; 25:191–201. https://doi.org/10.1093/hmg/ddv456 [PubMed]
- 52. Chen BH, Marioni RE, Colicino E, Peters MJ, Ward-Caviness CK, Tsai PC, Roetker NS, Just AC, Demerath EW, Guan W, Bressler J, Fornage M, Studenski S, et al. DNA methylation-based measures of biological age: meta-analysis predicting time to death. Aging (Albany NY). 2016; 8:1844–65. https://doi.org/10.18632/aging.101020 [PubMed]
- 53. van Iterson M, van Zwet EW, Heijmans BT, and BIOS Consortium. Controlling bias and inflation in epigenome- and transcriptome-wide association studies using the empirical null distribution. Genome Biol. 2017; 18:19. https://doi.org/10.1186/s13059-016-1131-9 [PubMed]
- 54. Seeboth A, McCartney DL, Wang Y, Hillary RF, Stevenson AJ, Walker RM, Campbell A, Evans KL, McIntosh AM, Hägg S, Deary IJ, Marioni RE. DNA methylation outlier burden, health, and ageing in generation scotland and the lothian birth cohorts of 1921 and 1936. Clin Epigenetics. 2020; 12:49. https://doi.org/10.1186/s13148-020-00838-0 [PubMed]
- 55. Chhabra D, Sharma S, Kho AT, Gaedigk R, Vyhlidal CA, Leeder JS, Morrow J, Carey VJ, Weiss ST, Tantisira KG, DeMeo DL. Fetal lung and placental methylation is associated with in utero nicotine exposure. Epigenetics. 2014; 9:1473–84. https://doi.org/10.4161/15592294.2014.971593 [PubMed]
- 56. Vyhlidal CA, Riffel AK, Haley KJ, Sharma S, Dai H, Tantisira KG, Weiss ST, Leeder JS. Cotinine in human placenta predicts induction of gene expression in fetal tissues. Drug Metab Dispos. 2013; 41:305–11. https://doi.org/10.1124/dmd.112.049999 [PubMed]
- 57. Morrow JD, Cho MH, Hersh CP, Pinto-Plata V, Celli B, Marchetti N, Criner G, Bueno R, Washko G, Glass K, Choi AMK, Quackenbush J, Silverman EK, DeMeo DL. DNA methylation profiling in human lung tissue identifies genes associated with COPD. Epigenetics. 2016; 11:730–739. https://doi.org/10.1080/15592294.2016.1226451 [PubMed]
- 58. Mansell G, Gorrie-Stone TJ, Bao Y, Kumari M, Schalkwyk LS, Mill J, Hannon E. Guidance for DNA methylation studies: statistical insights from the Illumina EPIC array. BMC Genomics. 2019; 20:366. https://doi.org/10.1186/s12864-019-5761-7 [PubMed]
- 59. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004; 5:R80. https://doi.org/10.1186/gb-2004-5-10-r80 [PubMed]
- 60. Aryee MJ, Jaffe AE, Corrada-Bravo H, Ladd-Acosta C, Feinberg AP, Hansen KD, Irizarry RA. Minfi: a flexible and comprehensive bioconductor package for the analysis of Infinium DNA methylation microarrays. Bioinformatics. 2014; 30:1363–69. https://doi.org/10.1093/bioinformatics/btu049 [PubMed]
- 61. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015; 43:e47. https://doi.org/10.1093/nar/gkv007 [PubMed]
- 62. Jiao C, Zhang C, Dai R, Xia Y, Wang K, Giase G, Chen C, Liu C. Positional effects revealed in Illumina methylation array and the impact on analysis. Epigenomics. 2018; 10:643–59. https://doi.org/10.2217/epi-2017-0105 [PubMed]
- 63. Wang C, Zhan X, Liang L, Abecasis GR, Lin X. Improved ancestry estimation for both genotyping and sequencing data using projection procrustes analysis and genotype imputation. Am J Hum Genet. 2015; 96:926–37. https://doi.org/10.1016/j.ajhg.2015.04.018 [PubMed]
- 64. Leek JT. Svaseq: removing batch effects and other unwanted noise from sequencing data. Nucleic Acids Res. 2014; 42:e161. https://doi.org/10.1093/nar/gku864 [PubMed]
- 65. Hansen KD. IlluminaHumanMethylation450kanno.ilmn12.hg19: Annotation for Illumina's 450k methylation arrays. R package version 0.6.0. 2016.
- 66. Peters TJ, Buckley MJ, Statham AL, Pidsley R, Samaras K, Lord RV, Clark SJ, Molloy PL. De novo identification of differentially methylated regions in the human genome. Epigenetics Chromatin. 2015; 8:6. https://doi.org/10.1186/1756-8935-8-6 [PubMed]
- 67. Carlson M. org.Hs.eg.db: Genome wide annotation for Human. R package version 3.8.2. 2019.
- 68. Kucera M, Isserlin R, Arkhangorodsky A, Bader GD. AutoAnnotate: a Cytoscape app for summarizing networks with semantic annotations. F1000Res. 2016; 5:1717. https://doi.org/10.12688/f1000research.9090.1 [PubMed]
- 69. Merico D, Isserlin R, Stueker O, Emili A, Bader GD. Enrichment map: a network-based method for gene-set enrichment visualization and interpretation. PLoS One. 2010; 5:e13984. https://doi.org/10.1371/journal.pone.0013984 [PubMed]
- 70. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003; 13:2498–504. https://doi.org/10.1101/gr.1239303 [PubMed]
- 71. Raudvere U, Kolberg L, Kuzmin I, Arak T, Adler P, Peterson H, Vilo J. g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update). Nucleic Acids Res. 2019; 47:W191–98. https://doi.org/10.1093/nar/gkz369 [PubMed]
- 72. McLean CY, Bristor D, Hiller M, Clarke SL, Schaar BT, Lowe CB, Wenger AM, Bejerano G. GREAT improves functional interpretation of cis-regulatory regions. Nat Biotechnol. 2010; 28:495–501. https://doi.org/10.1038/nbt.1630 [PubMed]